{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:40:04Z","timestamp":1786466404288,"version":"build-2736575974"},"reference-count":36,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Classic hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disorder characterized by the driver mutation BRAF V600E. Standard treatment with purine analogs (eg, cladribine) induces long-term remissions, but up to 25% of patients relapse early. Even when targeting BRAF V600E, residual HCL cells frequently persist in the bone marrow (BM). To identify additional biological alterations contributing to HCL persistence, we performed single-cell RNA sequencing of sorted primary HCL cells from long-term vs short-term cladribine responders (ST-R; &amp;gt;10 vs \u22643 years of progression-free survival) at diagnosis and from ST-R at diagnosis vs relapse. We identified a distinct HCL subcluster characterized by increased DUSP1, FOS, and JUND expression that was detected in all patients and persisted or even expanded at relapse. Cancer pathway analysis suggested enhanced tumor microenvironment dependence, as reflected by suppression of the p38 mitogen-activated protein kinase pathway. In the absence of a suitable BRAF V600E-mutated HCL cell line, we validated HAIR-M cells (BRAF D594E) as a bona fide experimental HCL model. The activating BRAF D594E mutation mimics V600E-induced downstream signaling that can be effectively targeted by BRAF inhibitors (BRAFi). HAIR-M coculture with BM stromal cells (BMSC) strongly induced DUSP1 and was accompanied by protection from BRAFi-induced HAIR-M apoptosis. The functional importance of DUSP1 was corroborated by showing that BMSC-induced protection from cell death could be overcome by DUSP1 inhibition. Our results may set the stage for future clinical testing of DUSP1 inhibition to eliminate minimal residual disease and prevent relapse in HCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019057","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:58:52Z","timestamp":1779879532000},"page":"5238-5249","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2066-7377","authenticated-orcid":false,"given":"Jan-Paul","family":"Bohn","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7759-7807","authenticated-orcid":false,"given":"Alexandra","family":"Scheiber","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9584-7842","authenticated-orcid":false,"given":"Gregor","family":"Sturm","sequence":"additional","affiliation":[{"name":"2Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria"},{"name":"3Boehringer Ingelheim International Pharma GmbH & Co KG, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0489-9921","authenticated-orcid":false,"given":"Thomas","family":"Maurer","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mair","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1238-9530","authenticated-orcid":false,"given":"Valentina","family":"Kugler","sequence":"additional","affiliation":[{"name":"4Institute of Molecular Biology and Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Feichtner","sequence":"additional","affiliation":[{"name":"4Institute of Molecular Biology and Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Fritz","sequence":"additional","affiliation":[{"name":"5Tyrolean Cancer Research Institute, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-3075","authenticated-orcid":false,"given":"Omar","family":"Torres-Quesada","sequence":"additional","affiliation":[{"name":"6Institute of Medical Biochemistry, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"Jaeger","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-5988","authenticated-orcid":false,"given":"Roland","family":"Huber","sequence":"additional","affiliation":[{"name":"8Bioinformatics Institute, Agency for Science, Technology and Research, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0158-0687","authenticated-orcid":false,"given":"Sophia","family":"Daum","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-9995","authenticated-orcid":false,"given":"Agnieszka","family":"Martowicz","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Redlinger","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7747-3012","authenticated-orcid":false,"given":"Andreas","family":"Pircher","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-1974","authenticated-orcid":false,"given":"Sieghart","family":"Sopper","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-7351","authenticated-orcid":false,"given":"Zlatko","family":"Trajanoski","sequence":"additional","affiliation":[{"name":"2Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-4713","authenticated-orcid":false,"given":"Eduard","family":"Stefan","sequence":"additional","affiliation":[{"name":"4Institute of Molecular Biology and Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria"},{"name":"5Tyrolean Cancer Research Institute, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-6954","authenticated-orcid":false,"given":"Stefan","family":"Salcher","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-075X","authenticated-orcid":false,"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine V, Hematology & Oncology, Comprehensive Cancer Center Innsbruck and Tyrolean Cancer Research Institute, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"7","key":"2026081110273186500_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2026081110273186500_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10","key":"2026081110273186500_bib3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2009-10-251645","article-title":"Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine","volume":"115","author":"Sigal","year":"2010","journal-title":"Blood"},{"issue":"24","key":"2026081110273186500_bib4","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"2026081110273186500_bib5","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2026081110273186500_bib6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia","volume":"141","author":"Kreitman","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2026081110273186500_bib7","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2017-01-765107","article-title":"Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2026081110273186500_bib8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2015-04-643361","article-title":"Recurrent CDKN1B (p27) mutations in hairy cell leukemia","volume":"126","author":"Dietrich","year":"2015","journal-title":"Blood"},{"issue":"48","key":"2026081110273186500_bib9","doi-asserted-by":"crossref","first-page":"28866","DOI":"10.18632\/oncotarget.25601","article-title":"New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes","volume":"9","author":"Maitre","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"2026081110273186500_bib10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41375-023-01823-1","article-title":"The genomic landscape and clonal evolutionary trajectory of classical hairy cell leukemia","volume":"37","author":"Moreno Rueda","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"2026081110273186500_bib11","doi-asserted-by":"crossref","first-page":"7780","DOI":"10.3390\/ijms22157780","article-title":"The biology of classic hairy cell leukemia","volume":"22","author":"Bohn","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2026081110273186500_bib12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2026081110273186500_bib13","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1038\/sj.onc.1206398","article-title":"Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways","volume":"22","author":"Kamiguti","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"2026081110273186500_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2012.163","article-title":"Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins","volume":"27","author":"Weston-Bell","year":"2013","journal-title":"Leukemia"},{"issue":"22","key":"2026081110273186500_bib15","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2011-12-400374","article-title":"Absence of BRAF-V600E in the human cell lines BONNA-12, ESKOL, HAIR-M, and HC-1 questions their origin from hairy cell leukemia","volume":"119","author":"Tiacci","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2026081110273186500_bib16","doi-asserted-by":"crossref","first-page":"1503.e8-1520.e8","DOI":"10.1016\/j.ccell.2022.10.008","article-title":"High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer","volume":"40","author":"Salcher","year":"2022","journal-title":"Cancer cell"},{"issue":"4","key":"2026081110273186500_bib17","doi-asserted-by":"crossref","first-page":"103475","DOI":"10.1016\/j.xpro.2024.103475","article-title":"Profiling low-mRNA content cells in complex human tissues using BD Rhapsody single-cell analysis","volume":"5","author":"Scheiber","year":"2024","journal-title":"STAR Protoc"},{"issue":"9","key":"2026081110273186500_bib18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/nchembio.190","article-title":"Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages","volume":"5","author":"Molina","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2026081110273186500_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20031175","article-title":"Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors","volume":"199","author":"Basso","year":"2004","journal-title":"J Exp Med"},{"issue":"8","key":"2026081110273186500_bib20","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00432-022-04010-4","article-title":"Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy","volume":"148","author":"Maitre","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2026081110273186500_bib21","doi-asserted-by":"crossref","first-page":"10699","DOI":"10.1038\/s41598-019-46932-z","article-title":"DMSO cryopreservation is the method of choice to preserve cells for droplet-based single-cell RNA sequencing","volume":"9","author":"Wohnhaas","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"2026081110273186500_bib22","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.4110\/in.2020.20.e34","article-title":"Effects of cryopreservation and thawing on single-cell transcriptomes of human T cells","volume":"20","author":"Lee","year":"2020","journal-title":"Immune Netw"},{"issue":"17","key":"2026081110273186500_bib23","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/jcmm.17890","article-title":"Hairy cell leukaemia with unusual BRAF mutations","volume":"27","author":"Maitre","year":"2023","journal-title":"J Cell Mol Med"},{"issue":"3","key":"2026081110273186500_bib24","doi-asserted-by":"crossref","first-page":"563.e11-575.e11","DOI":"10.1016\/j.cell.2022.01.003","article-title":"Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients","volume":"185","author":"Nguyen","year":"2022","journal-title":"Cell"},{"issue":"2","key":"2026081110273186500_bib25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nat Med"},{"issue":"49","key":"2026081110273186500_bib26","doi-asserted-by":"crossref","first-page":"31105","DOI":"10.1073\/pnas.2012150117","article-title":"Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies","volume":"117","author":"Mayrhofer","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026081110273186500_bib27","doi-asserted-by":"crossref","first-page":"eaav8463","DOI":"10.1126\/sciadv.aav8463","article-title":"BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS","volume":"5","author":"Rock","year":"2019","journal-title":"Sci Adv"},{"issue":"10","key":"2026081110273186500_bib28","first-page":"830.e3-843.e3","article-title":"Resistor: an algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures","volume":"13","author":"Guerin","year":"2022","journal-title":"Cell Syst"},{"key":"2026081110273186500_bib29","doi-asserted-by":"crossref","first-page":"RP94755","DOI":"10.7554\/eLife.94755","article-title":"Impact of protein and small molecule interactions on kinase conformations","volume":"13","author":"Kugler","year":"2024","journal-title":"Elife"},{"issue":"10","key":"2026081110273186500_bib30","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-01-0324","article-title":"CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD","volume":"101","author":"Nicolaou","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2026081110273186500_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1124\/pr.107.00106","article-title":"Mitogen-activated protein (MAP) kinase\/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer","volume":"60","author":"Boutros","year":"2008","journal-title":"Pharmacol Rev"},{"issue":"12","key":"2026081110273186500_bib32","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/leu.2012.149","article-title":"A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK-JNK pathways","volume":"26","author":"Kitagawa","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"2026081110273186500_bib33","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1073\/pnas.0900780106","article-title":"(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway","volume":"106","author":"Pratilas","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2026081110273186500_bib34","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor adaptation and resistance to RAF inhibitors","volume":"19","author":"Lito","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2026081110273186500_bib35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nm.4310","article-title":"Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia","volume":"23","author":"Kesarwani","year":"2017","journal-title":"Nat Med"},{"issue":"8","key":"2026081110273186500_bib36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41375-023-01959-0","article-title":"MAPK-negative feedback regulation confers dependence to JAK2(V617F) signaling","volume":"37","author":"Kesarwani","year":"2023","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5238\/2535579\/blooda_adv-2025-019057-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5238\/2535579\/blooda_adv-2025-019057-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:17Z","timestamp":1786462997000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5238\/568739\/DUSP1-is-a-key-driver-of-disease-persistence-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":36,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019057","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,29]]}}}